Published in Clin Sci (Lond) on September 01, 1995
Empirical evidence of design-related bias in studies of diagnostic tests. JAMA (1999) 12.96
Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet (2001) 8.54
The long-term clinical course of acute deep venous thrombosis. Ann Intern Med (1996) 6.87
Deep-vein thrombosis and the incidence of subsequent symptomatic cancer. N Engl J Med (1992) 5.48
C-reactive protein as a cardiovascular risk factor: more than an epiphenomenon? Circulation (1999) 4.40
Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low-molecular-weight heparin administered at home. The Tasman Study Group. N Engl J Med (1996) 4.10
Subcutaneous fondaparinux versus intravenous unfractionated heparin in the initial treatment of pulmonary embolism. N Engl J Med (2003) 3.94
Safety of transesophageal echocardiography. A multicenter survey of 10,419 examinations. Circulation (1991) 3.70
Frequency of pregnancy-related venous thromboembolism in anticoagulant factor-deficient women: implications for prophylaxis. Ann Intern Med (1996) 3.42
Pharmacological strategies to decrease excessive blood loss in cardiac surgery: a meta-analysis of clinically relevant endpoints. Lancet (1999) 2.77
LAD-right ventricular fistula complicating PTCA: another case. Cathet Cardiovasc Diagn (1997) 2.55
[Treatment of patients with diabetes mellitus type 2 and coronary artery disease]. Ned Tijdschr Geneeskd (2006) 2.51
Oral anticoagulation self-management and management by a specialist anticoagulation clinic: a randomised cross-over comparison. Lancet (2000) 2.49
How soon should drainage tubes be removed after cardiac operations? Ann Thorac Surg (1989) 2.37
Incidence of recurrent thromboembolic and bleeding complications among patients with venous thromboembolism in relation to both malignancy and achieved international normalized ratio: a retrospective analysis. J Clin Oncol (2000) 2.35
Extensive screening for occult malignant disease in idiopathic venous thromboembolism: a prospective randomized clinical trial. J Thromb Haemost (2004) 2.28
International clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer. J Thromb Haemost (2013) 2.24
Importance of left atrial appendage flow as a predictor of thromboembolic events in patients with atrial fibrillation. Eur Heart J (1999) 2.22
Long-term outcome of patients with multiple (> or = 3) noninfected transvenous leads: a clinical and echocardiographic study. Pacing Clin Electrophysiol (2000) 2.22
Activation of a retroviral membrane fusion protein: soluble receptor-induced liposome binding of the ALSV envelope glycoprotein. J Cell Biol (1997) 2.21
Non-pharmaceutical measures for prevention of post-thrombotic syndrome. Cochrane Database Syst Rev (2004) 2.16
High plasma concentration of factor VIIIc is a major risk factor for venous thromboembolism. Thromb Haemost (2000) 2.15
Plasma levels of matrix metalloproteinase-9: a possible diagnostic marker of successful endovascular aneurysm repair. Eur J Vasc Endovasc Surg (2011) 2.14
Procoagulant and proinflammatory activity in acute coronary syndromes. Cardiovasc Res (1998) 2.12
Comparison of idrabiotaparinux with vitamin K antagonists for prevention of thromboembolism in patients with atrial fibrillation: the Borealis-Atrial Fibrillation Study. J Thromb Haemost (2014) 2.03
Prediction of the risk of bleeding during anticoagulant treatment for venous thromboembolism. Arch Intern Med (1999) 2.00
Deep-vein thrombosis. Lancet (1999) 1.98
Triage of patients for short term observation after elective coronary angioplasty. Heart (2000) 1.97
C-reactive protein colocalizes with complement in human hearts during acute myocardial infarction. Circulation (1997) 1.94
Time course of arteriogenesis following femoral artery occlusion in the rabbit. Cardiovasc Res (2001) 1.84
Fixed dose subcutaneous low molecular weight heparins versus adjusted dose unfractionated heparin for venous thromboembolism. Cochrane Database Syst Rev (2004) 1.84
Treatment of intermittent claudication with physical training, smoking cessation, pentoxifylline, or nafronyl: a meta-analysis. Arch Intern Med (1999) 1.81
The risk of recurrent venous thromboembolism in patients with an Arg506-->Gln mutation in the gene for factor V (factor V Leiden). N Engl J Med (1997) 1.75
Quantification of regional contractile function after infarction: strain analysis superior to wall thickening analysis in discriminating infarct from remote myocardium. J Am Coll Cardiol (2001) 1.73
Comparison of a clinical probability estimate and two clinical models in patients with suspected pulmonary embolism. ANTELOPE-Study Group. Thromb Haemost (2000) 1.73
A prospective study of asymptomatic carriers of the factor V Leiden mutation to determine the incidence of venous thromboembolism. Ann Intern Med (2001) 1.72
Relationship between preoperative viability and postoperative improvement in LVEF and heart failure symptoms. J Nucl Med (2001) 1.70
Safety of outpatient treatment in acute pulmonary embolism. J Thromb Haemost (2010) 1.69
Diagnosis of arterial disease of the lower extremities with duplex ultrasonography. Br J Surg (1996) 1.68
Decision analysis for cancer screening in idiopathic venous thromboembolism. J Thromb Haemost (2005) 1.65
Lipoprotein lipase activity is associated with severity of angina pectoris. REGRESS Study Group. Circulation (2000) 1.65
Screening for occult cancer in patients with acute deep vein thrombosis or pulmonary embolism. J Thromb Haemost (2004) 1.63
Prediction of apical thrombus formation in acute myocardial infarction based on left ventricular spatial flow pattern. J Am Coll Cardiol (1990) 1.61
Is the prevalence of the factor V Leiden mutation in patients with pulmonary embolism and deep vein thrombosis really different? Thromb Haemost (1999) 1.60
Apoptosis in myocardial ischaemia and infarction. J Clin Pathol (2002) 1.59
Recurrence of venous thromboembolism in patients with familial thrombophilia. Arch Intern Med (1997) 1.57
Bleeding classification in clinical trials: observer variability and clinical relevance. Thromb Haemost (1997) 1.56
Pharmacological modulation of the human collateral vascular resistance in acute and chronic coronary occlusion assessed by intracoronary blood flow velocity analysis in an angioplasty model. Circulation (1997) 1.55
Low-molecular-weight heparin in the treatment of patients with venous thromboembolism. The Columbus Investigators. N Engl J Med (1997) 1.54
Magnetic resonance angiography of anomalous coronary arteries. A new gold standard for delineating the proximal course? Circulation (1995) 1.53
Value of coronary stenotic flow velocity acceleration in prediction of angiographic restenosis following balloon angioplasty. Eur Heart J (2002) 1.52
Persistent precordial "hyperacute" T-waves signify proximal left anterior descending artery occlusion. Heart (2009) 1.51
Prediction of restenosis after coronary balloon angioplasty. Results of PICTURE (Post-IntraCoronary Treatment Ultrasound Result Evaluation), a prospective multicenter intracoronary ultrasound imaging study. Circulation (1997) 1.51
C-reactive protein and complement depositions in human infarcted myocardium are more extensive in patients with reinfarction or upon treatment with reperfusion. Eur J Clin Invest (2004) 1.50
Effects on coagulation of levonorgestrel- and desogestrel-containing low dose oral contraceptives: a cross-over study. Thromb Haemost (2000) 1.49
Prediction of surgical strategy in mitral valve regurgitation based on echocardiography. Interuniversity Cardiology Institute of The Netherlands. Am J Cardiol (1997) 1.48
Brain areas specific for attentional load in a motion-tracking task. J Cogn Neurosci (2001) 1.48
Microbubbles and ultrasound: from diagnosis to therapy. Eur J Echocardiogr (2004) 1.47
Accuracy of single-detector spiral CT in the diagnosis of pulmonary embolism: a prospective multicenter cohort study of consecutive patients with abnormal perfusion scintigraphy. J Thromb Haemost (2005) 1.46
Left ventricular systolic and diastolic function in septic shock. Intensive Care Med (1997) 1.45
The prognostic value of pre-procedural plasma C-reactive protein in patients undergoing elective coronary angioplasty. Eur Heart J (2002) 1.45
Time course of functional recovery of stunned and hibernating segments after surgical revascularization. Circulation (2001) 1.44
Biplane transesophageal color-flow Doppler imaging in assessing severity of mitral regurgitation: influence of hemodynamic circumstances and mechanism of regurgitation. J Cardiothorac Vasc Anesth (1996) 1.44
Outcome of the subsequent pregnancy after a first loss in women with the factor V Leiden or prothrombin 20210A mutations. J Thromb Haemost (2007) 1.44
Carbon-11 acetate as a tracer of myocardial oxygen consumption. Eur J Nucl Med (2001) 1.44
Transesophageal echocardiography for early cardioversion of atrial fibrillation. Am J Cardiol (2000) 1.43
Once versus twice daily LMWH for the initial treatment of venous thromboembolism. Cochrane Database Syst Rev (2005) 1.43
Microcirculatory investigations to determine the effect of spinal cord stimulation for critical leg ischemia: the Dutch multicenter randomized controlled trial. J Vasc Surg (1999) 1.43
Ruling out acute myocardial infarction early with two serial creatine kinase-MBmass determinations. Eur Heart J (1999) 1.43
A randomized cross-over study on the effects of levonorgestrel- and desogestrel-containing oral contraceptives on the anticoagulant pathways. Thromb Haemost (2000) 1.43
Hyperemic coronary flow after optimized intravascular ultrasound-guided balloon angioplasty and stent implantation. J Am Coll Cardiol (1999) 1.42
Treatment of deep venous thrombosis with low-molecular-weight heparins. A meta-analysis. Arch Intern Med (1995) 1.41
EVAR suitability is not a predictor for early and midterm mortality after open ruptured AAA repair. Eur J Vasc Endovasc Surg (2011) 1.41
Indications for coronary revascularisation: guidelines for the Netherlands. Heart (2000) 1.41
The QRS score: a promising new exercise score for detecting coronary artery disease based on exercise-induced changes of Q-, R- and S-waves: a relationship with myocardial ischaemia. Eur Heart J (1996) 1.41
Intracardiac thrombi and systemic embolization. Ann Intern Med (1986) 1.41
Duration of oral anticoagulant treatment in patients with venous thromboembolism and a deficiency of antithrombin, protein C or protein S--a decision analysis. Thromb Haemost (2000) 1.40
Influence of coronary artery bypass surgery on regional left ventricular wall motion: an intraoperative two-dimensional transesophageal echocardiographic study. J Cardiothorac Anesth (1987) 1.40
[Deep venous thrombosis: does recently improved knowledge lead to a real advance in the direction patient care?]. Ned Tijdschr Geneeskd (1996) 1.39
Evaluation of the long-term functional outcome assessed by myocardial perfusion scintigraphy following excimer laser angioplasty compared to balloon angioplasty in longer coronary lesions. Int J Card Imaging (2000) 1.39
[High-density lipoproteins]. Ned Tijdschr Geneeskd (1992) 1.38
Risk factors of arterial cardiovascular complications in patients with prior venous thromboembolism. Neth J Med (2011) 1.38
Transient permeabilization of cell membranes by ultrasound-exposed microbubbles is related to formation of hydrogen peroxide. Am J Physiol Heart Circ Physiol (2006) 1.37
Cell therapy for ischaemic heart disease: focus on the role of resident cardiac stem cells. Neth Heart J (2009) 1.35
Left ventricular thrombus in acute myocardial infarction. Eur Heart J (1996) 1.33
Increased fibrinolytic activity during use of oral contraceptives is counteracted by an enhanced factor XI-independent down regulation of fibrinolysis: a randomized cross-over study of two low-dose oral contraceptives. Thromb Haemost (2000) 1.32